Scienture Holdings shares surge 13.00% after-hours after launching FDA-approved high-strength naloxone nasal spray REZENOPY in partnership with Summit Biosciences.

Scienture Holdings surged 13.00% in after-hours trading following an announcement about the commercial launch of REZENOPY®, a high-strength 10 mg naloxone HCl nasal spray. The company, through an exclusive agreement with Summit Biosciences Inc., will oversee U.S. commercialization, planning to load the product into wholesale channels by Q1 2026 with availability expected in early Q2 2026. This development expands Scienture’s product portfolio to address a critical unmet need in opioid overdose treatment, aligning with the FDA’s April 2024 approval. The news underscores the company’s strategic positioning in a high-growth therapeutic area, bolstering investor confidence in its long-term revenue potential and operational capabilities.